Raul Rodriguez compensation by year
RIGEL PHARMACEUTICALS Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $618,000 | $618,000 | $636,540 | $649,271 | $662,256 | $662,256 | $700,000 | $728,000 | $757,000 | $787,405 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $484,000 | $561,000 | $508,000 | $951,327 |
| Option awards | $1,315,680 | $1,180,636 | $2,733,225 | $1,553,287 | $1,992,765 | $2,448,705 | $1,287,120 | $1,706,280 | $1,175,160 | $2,241,570 |
| Non-equity incentive | $241,020 | $370,800 | $607,741 | $350,606 | $298,015 | $298,015 | $365,400 | $414,960 | $522,330 | $634,649 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $3,354 | $3,354 | $3,354 | $8,954 | $10,848 | $19,065 | $27,600 | $30,550 | $36,198 | $43,854 |
| Total | $2,178,054 | $2,172,790 | $3,980,860 | $2,562,118 | $2,963,884 | $3,428,041 | $2,864,120 | $3,440,790 | $2,998,688 | $4,658,805 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 3, 2026, accession 0001034842-26-000023, and prior-year filings. Open the filing on EDGAR.
How this page was built: the RIGEL PHARMACEUTICALS INC filed document, accession 0001034842-26-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 42,300 | $1,811,709 | — |
| RSU | 26,667 | $1,142,148 | — |
| RSU | 15,000 | $642,450 | — |
| RSU | 5,000 | $214,150 | — |
| Option | 834 | — | $24.20 |
| Option | 44,028 | — | $22.49 |
| Option | 21,681 | — | $12.70 |
| Option | 16,249 | — | $18.70 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RIGEL PHARMACEUTICALS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 3, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-01 | Tax withholding | — | 2,424 | $47.50 | 273,362 |
| 2026-06-17 | Grant or award derivative | — | 31,700 | $0.00 | 31,700 |
| 2026-06-01 | Tax withholding | — | 2,424 | $29.86 | 279,593 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
RIGEL PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Raul Rodriguez · this page | President and Chief Executive Officer | $4,658,805 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,831,604 |
| Lisa Rojkjaer | Executive Vice President and Chief Medical Officer | $1,830,175 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,822,409 |
| Raymond Furey | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $1,769,502 |
Board service
RIGEL PHARMACEUTICALS board · FY2023–FY2025How this board is paid
Company policy: RIGEL PHARMACEUTICALS pays directors a $50,000 cash retainer. As stated in RIGEL PHARMACEUTICALS's FY2025 proxy.
Committees
Finance
The full RIGEL PHARMACEUTICALS compensation record
free company briefThis page is one person within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RIGEL PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RIGEL PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RIGEL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RIGL
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.